Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Subject To More Oversight Following User Fee Bill Passage

This article was originally published in The Gray Sheet

Executive Summary

The legislation, awaiting the signature of the president, will bring greater scrutiny of device center activities by Congress and industry.

You may also be interested in...



Obamacare Repeal May Be Delaying User-Fee Bills, Rep. DeGette Says

The House Energy and Commerce Committee Democrat says few in-depth member talks about user-fee bills have taken place because of a focus on Affordable Care Act repeal and replacement.

Device Reg Issues In Play As FDA Kicks Off User Fee Renewal Effort

FDA will host a public meeting July 13 to hear public input in advance of agency-industry negotiations to reauthorize the device user-fee program. Industry appears to feel better about the device-review program than it did during the prior user-fee program, but what the top issues will be during negotiations this time around remain to be seen. Ongoing reform efforts in Congress will impact the process.

Draft Guidance Docs Should Be Transitory, Industry Insists

Device industry advocates stressed to CDRH during a meeting last week that draft-guidance documents need to more routinely be finalized or withdrawn in an expedited manner, and that agency staffers must resist using the out-for-comment document as if they are settled policy.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT031353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel